Desmond Barton

Dr. Desmond Barton


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Gynecologic Oncology
Verified
Journal Article
Closed access
DBDesmond Barton
Desmond Barton
TAT. Adib
T. Adib
JBJ. Butler
J. Butler

20 November 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
FGFaiza Gaba
Faiza Gaba
OBOleg Blyuss
Oleg Blyuss
DCDhivya Chandrasekaran
Dhivya Chandrasekaran
Nicolò BizzarriNicolò Bizzarri
Nicolò Bizzarri
BRBasel Refky
Basel Refky
OCon behalf of the GO SOAR Collaborative
on behalf of the GO SOAR Collaborative
For women achieving clinical remission after the completion of initial treatment for epithelial ovarian cancer, 80% with advanced-stage disease will develop recurrence. However, the standard treatment of women with recurrent platinum-sensitive diseases remains poorly defined. Secondary (SCS), tertiary (TCS) or quaternary (QCS) cytoreduction surgery for recurrence has been suggested to be associated with increased overall survival (OS). We searched five databases for studies reporting death rate, OS, cytoreduction rates, post-operative morbidity/mortality and diagnostic models predicting complete cytoreduction in a platinum-sensitive disease recurrence setting. Death rates calculated from raw data were pooled based on a random-effects model. Meta-regression/linear regression was performed to explore the role of complete or optimal cytoreduction as a moderator. Pooled death rates were 45%, 51%, 66% for SCS, TCS and QCS, respectively. Median OS for optimal cytoreduction ranged from 16–91, 24–99 and 39–135 months for SCS, TCS and QCS, respectively. Every 10% increase in complete cytoreduction rates at SCS corresponds to a 7% increase in median OS. Complete cytoreduction rates ranged from 9–100%, 35–90% and 33–100% for SCS, TCS and QCS, respectively. Major post-operative thirty-day morbidity was reported to range from 0–47%, 13–33% and 15–29% for SCS, TCS and QCS, respectively. Thirty-day post-operative mortality was 0–6%, 0–3% and 0–2% for SCS, TCS and QCS, respectively. There were two externally validated diagnostic models predicting complete cytoreduction at SCS, but none for TCS and QCS. In conclusion, our data confirm that maximal effort higher order cytoreductive surgery resulting in complete cytoreduction can improve survival.

23 November 2011 in Hereditary Cancer in Clinical Practice
Verified
Journal Article
Open access
PDF file
MNMarielle Ae Nobbenhuis
Marielle Ae Nobbenhuis
EBElizabeth Bancroft
Elizabeth Bancroft
EMEleanor Moskovic
Eleanor Moskovic
FLFiona Lennard
Fiona Lennard
PPPaul Pharoah
Paul Pharoah
RERos Eeles
Ros Eeles
We assessed ovarian cancer screening outcomes in women with a positive family history of ovarian cancer divided into a low-, moderate- or high-risk group for development of ovarian cancer. 545 women with a positive family history of ovarian cancer referred to the Ovarian Screening Service at the Royal Marsden Hospital, London from January 2000- December 2008 were included. They were stratified into three risk-groups according to family history (high-, moderate- and low-risk) of developing ovarian cancer and offered annual serum CA 125 and transvaginal ultrasound screening. The high-risk group was offered genetic testing. The median age at entry was 44 years. The number of women in the high, moderate and low-risk groups was 397, 112, and 36, respectively. During 2266 women years of follow-up two ovarian cancer cases were found: one advanced stage at her fourth annual screening, and one early stage at prophylactic bilateral salpingo-oophorectomy (BSO). Prophylactic BSO was performed in 138 women (25.3%). Forty-three women had an abnormal CA125, resulting in 59 repeat tests. The re-call rate in the high, moderate and low-risk group was 14%, 3% and 6%. Equivocal transvaginal ultrasound results required 108 recalls in 71 women. The re-call rate in the high, moderate, and low-risk group was 25%, 6% and 17%. No early stage ovarian cancer was picked up at annual screening and a significant number of re-calls for repeat screening tests was identified.

24 January 2017 in The Obstetrician & Gynaecologist
Verified
Journal Article
Closed access
PDF file
DKDesiree F Kolomainen
Desiree F Kolomainen
JRJulia Riley
Julia Riley
JWJayne Wood
Jayne Wood
DBDesmond Barton
Desmond Barton

17 April 2017 in The Obstetrician & Gynaecologist
Verified
Journal Article
Closed access
PDF file
DKDesiree F Kolomainen
Desiree F Kolomainen
DBDesmond Barton
Desmond Barton

11 March 2025
Verified
Book Chapter
Closed access
PDF file
DBDesmond Barton
Desmond Barton
OHOwen M. Heath
Owen M. Heath
RSRasheed Shahnawaz
Rasheed Shahnawaz
QSQiu Sheng
Qiu Sheng
TAThompson Alan
Thompson Alan
KPKumar Pardeep
Kumar Pardeep